Traws Pharma (TRAW) announced the retirement of Werner Cautreels, CEO, effective on or about close of business on March 31 after the company files its annual report on Form 10-K with the SEC. Iain Dukes will assume the role of interim CEO. In addition to his new responsibilities, Dukes will continue to serve as Traws’ chairman.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRAW:
- Traws Pharma presents data on COVID-19 candidate ratutrelvir at ICAR
- Traws Pharma announces results from study of tivoxavir marboxil in bird flu
- Traws Pharma presents data on tivoxavir marboxil for bird flu treatment
- Traws Pharma reports results from bird flu model for tivoxavir marboxil
- Traws Pharma Regains Nasdaq Compliance with $20M Financing